A Pentavalent Epstein-Barr Virus-Like Particle Vaccine Elicits High Titers of Neutralizing Antibodies against Epstein-Barr Virus Infection in Immunized Rabbits
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Pentavalent Epstein-Barr Virus-Like Particle Vaccine Elicits High Titers of Neutralizing Antibodies against Epstein-Barr Virus Infection in Immunized Rabbits
Authors
Keywords
-
Journal
Vaccines
Volume 8, Issue 2, Pages 169
Publisher
MDPI AG
Online
2020-04-07
DOI
10.3390/vaccines8020169
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Progress in EBV Vaccines
- (2019) Dwain G. van Zyl et al. Frontiers in Oncology
- Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Uganda and Tanzania
- (2019) Zacchaeus Anywaine et al. JOURNAL OF INFECTIOUS DISEASES
- Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation
- (2019) Theresa Kaeuferle et al. Journal of Hematology & Oncology
- Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells
- (2019) Wei Bu et al. IMMUNITY
- Heterologous prime-boost vaccination protects against EBV antigen–expressing lymphomas
- (2019) Julia Rühl et al. JOURNAL OF CLINICAL INVESTIGATION
- A multivalent Kaposi sarcoma-associated herpesvirus-like particle vaccine capable of eliciting high titers of neutralizing antibodies in immunized rabbits
- (2019) David H. Mulama et al. VACCINE
- The T-cell Response to Epstein-Barr Virus–New Tricks From an Old Dog
- (2019) Heather M. Long et al. Frontiers in Immunology
- Identification of multiple potent neutralizing and non-neutralizing antibodies against Epstein-Barr virus gp350 protein with potential for clinical application and as reagents for mapping immunodominant epitopes
- (2019) Lorraine Z. Mutsvunguma et al. VIROLOGY
- An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus
- (2018) Joost Snijder et al. IMMUNITY
- Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins
- (2018) Adrián Lázaro-Frías et al. JOURNAL OF VIROLOGY
- Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity
- (2018) John B. Harley et al. NATURE GENETICS
- A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge
- (2018) Arban Domi et al. Scientific Reports
- Adoptive T Cell Therapy for Epstein–Barr Virus Complications in Patients With Primary Immunodeficiency Disorders
- (2018) Lauren P. McLaughlin et al. Frontiers in Immunology
- Ephrin receptor A2 is an epithelial cell receptor for Epstein–Barr virus entry
- (2018) Hua Zhang et al. Nature Microbiology
- Ephrin receptor A2 is a functional entry receptor for Epstein–Barr virus
- (2018) Jia Chen et al. Nature Microbiology
- Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice
- (2018) Flavia Chiuppesi et al. JOURNAL OF VIROLOGY
- Molecular mechanisms of EBV-driven cell cycle progression and oncogenesis
- (2018) Huali Yin et al. MEDICAL MICROBIOLOGY AND IMMUNOLOGY
- Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice
- (2018) Dwain G. van Zyl et al. PLoS Pathogens
- Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles
- (2017) Marc Schweneker et al. JOURNAL OF VIROLOGY
- Production of virus-like particles for vaccines
- (2017) J. Fuenmayor et al. New Biotechnology
- BALB/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8.1, gB, and gH/gL induced comparable serum neutralizing antibody activity to UV-inactivated KSHV
- (2017) Anne K. Barasa et al. Oncotarget
- Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus
- (2017) Anna Bootz et al. PLoS Pathogens
- Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector
- (2017) Ziqing Liu et al. Scientific Reports
- Higher Risk for Hematological Malignancies in Inflammatory Bowel Disease: A Nationwide Population-based Study in Taiwan
- (2016) Li-Hui Wang et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Exploiting Mucosal Immunity for Antiviral Vaccines
- (2016) Akiko Iwasaki Annual Review of Immunology
- Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines
- (2016) Iain D. Milligan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial
- (2016) Milagritos D Tapia et al. LANCET INFECTIOUS DISEASES
- Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350
- (2016) Xinle Cui et al. VACCINE
- Structural basis for Epstein–Barr virus host cell tropism mediated by gp42 and gHgL entry glycoproteins
- (2016) Karthik Sathiyamoorthy et al. Nature Communications
- Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice
- (2016) Elizabeth M. Perez et al. Oncotarget
- Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site
- (2015) Masaru Kanekiyo et al. CELL
- EBV glycoproteins: where are we now?
- (2015) Lindsey M Hutt-Fletcher Future Virology
- A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice
- (2015) Javier Ogembo et al. Journal of Translational Medicine
- Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific
- (2015) Tina M. Cairns et al. JOURNAL OF VIROLOGY
- A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein-Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer
- (2014) G. S. Taylor et al. CLINICAL CANCER RESEARCH
- How the Current West African Ebola Virus Disease Epidemic Is Altering Views on the Need for Vaccines and Is Galvanizing a Global Effort to Field-Test Leading Candidate Vaccines
- (2014) M. M. Levine et al. JOURNAL OF INFECTIOUS DISEASES
- Fold Rise in Antibody Titers by Measured by Glycoprotein-Based Enzyme-Linked Immunosorbent Assay Is an Excellent Correlate of Protection for a Herpes Zoster Vaccine, Demonstrated via the Vaccine Efficacy Curve
- (2014) Peter B. Gilbert et al. JOURNAL OF INFECTIOUS DISEASES
- Mechanism for neutralizing activity by the anti-CMV gH/gL monoclonal antibody MSL-109
- (2014) A. E. Fouts et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Assembly and Architecture of the EBV B Cell Entry Triggering Complex
- (2014) Karthik Sathiyamoorthy et al. PLoS Pathogens
- Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein-Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients
- (2013) E. P. Hui et al. CANCER RESEARCH
- A Paradigm Shift: Vaccine-Induced Antibodies as an Immune Correlate of Protection Against Herpes Simplex Virus Type 1 Genital Herpes
- (2013) S. Awasthi et al. JOURNAL OF INFECTIOUS DISEASES
- The need and challenges for development of an Epstein-Barr virus vaccine
- (2013) Jeffrey I. Cohen et al. VACCINE
- Human Complement Receptor Type 1/CD35 Is an Epstein-Barr Virus Receptor
- (2013) Javier G. Ogembo et al. Cell Reports
- Efficacy Results of a Trial of a Herpes Simplex Vaccine
- (2012) Robert B. Belshe et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fusion of Epstein-Barr Virus with Epithelial Cells Can Be Triggered by v 5 in Addition to v 6 and v 8, and Integrin Binding Triggers a Conformational Change in Glycoproteins gHgL
- (2011) L. S. Chesnokova et al. JOURNAL OF VIROLOGY
- A Virus-Like Particle-Based Epstein-Barr Virus Vaccine
- (2011) R. Ruiss et al. JOURNAL OF VIROLOGY
- Anti-Epstein–Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel
- (2011) KL Munger et al. Multiple Sclerosis Journal
- Fusing structure and function: a structural view of the herpesvirus entry machinery
- (2011) Sarah A. Connolly et al. NATURE REVIEWS MICROBIOLOGY
- High Cleavage Efficiency of a 2A Peptide Derived from Porcine Teschovirus-1 in Human Cell Lines, Zebrafish and Mice
- (2011) Jin Hee Kim et al. PLoS One
- Epstein-Barr Virus: An Important Vaccine Target for Cancer Prevention
- (2011) J. I. Cohen et al. Science Translational Medicine
- An Updated Meta-Analysis of Risk of Multiple Sclerosis following Infectious Mononucleosis
- (2010) Adam E. Handel et al. PLoS One
- The IC50 of anti-Pfs25 antibody in membrane-feeding assay varies among species
- (2010) Lediya Cheru et al. VACCINE
- Fusion of epithelial cells by Epstein-Barr virus proteins is triggered by binding of viral glycoproteins gHgL to integrins v 6 or v 8
- (2009) L. S. Chesnokova et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Phase I Trial of Epstein-Barr Virus Gp350 Vaccine for Children With Chronic Kidney Disease Awaiting Transplantation
- (2009) Lesley Rees et al. TRANSPLANTATION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now